Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

3KEYNOTE-119 (PDL1 CPS>1), 2019 KEYNOTE-119 (PDL1 CPS>10), 2019 KEYNOTE-119 (all population), 20192IMpassion-130 (all population), 2018 IMpassion-130 (PDL1>1%), 20181IMpassion-031 (all population), 20202IMpassion-131 (PD-L1 > 1%), 2020 IMpassion-131 (all population), 20201EMBRACA, 20181OlympiAD, 20171OlympiA (BIG 6-13, NSABP B-55), 03KEYNOTE-355 (all population), 2020 KEYNOTE-355 (CPS>1), 2020 KEYNOTE-355 (CPS>10), 20202ASCENT (all population), 2021 ASCENT (patients without brain metastases), 20212PAKT (all population), 2020 PAKT (PIK3CA/AKT1/PTEN-altered), 20201LOTUS, 20171BrighTNess (velaparib-P-C (arm A) vs paclitaxel alone (arm C)), 2018atezolizumab plus nab-paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.18 [0.43; 3.26]1.18 [0.43;3.26]atezolizumab plus nab-paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.18 [0.43; 3.26]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel atezolizumab plus nab-paclitaxel better 0.73 [0.57; 0.94]0.73 [0.57;0.94]atezolizumab plus nab-paclitaxel vs. atezolizumab plus paclitaxel atezolizumab plus nab-paclitaxel better 0.73 [0.57; 0.94]atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel 1.45 [0.90; 2.33]1.45 [0.90;2.33]atezolizumab plus nab-paclitaxel vs. capivasertib plus paclitaxel 1.45 [0.90; 2.33]atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel 1.02 [0.62; 1.67]1.02 [0.62;1.67]atezolizumab plus nab-paclitaxel vs. ipatasertib plus paclitaxel 1.02 [0.62; 1.67]atezolizumab plus nab-paclitaxel vs. olaparib 0.91 [0.64; 1.28]0.91 [0.64;1.28]atezolizumab plus nab-paclitaxel vs. olaparib 0.91 [0.64; 1.28]atezolizumab plus nab-paclitaxel vs. pembrolizumab alone 0.90 [0.75; 1.09]0.90 [0.75;1.09]atezolizumab plus nab-paclitaxel vs. pembrolizumab alone 0.90 [0.75; 1.09]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.96 [0.80; 1.15]0.96 [0.80;1.15]atezolizumab plus nab-paclitaxel vs. pembrolizumab plus SoC 0.96 [0.80; 1.15]atezolizumab plus nab-paclitaxel vs. placebo 0.62 [0.37; 1.01]0.62 [0.37;1.01]atezolizumab plus nab-paclitaxel vs. placebo 0.62 [0.37; 1.01]atezolizumab plus nab-paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 1.64 [1.33; 2.03]1.64 [1.33;2.03]atezolizumab plus nab-paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 1.64 [1.33; 2.03]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.81 [0.70; 0.94]0.81 [0.70;0.94]atezolizumab plus nab-paclitaxel vs. Standard of Care (SoC) atezolizumab plus nab-paclitaxel better 0.81 [0.70; 0.94]atezolizumab plus nab-paclitaxel vs. talazoparib 0.96 [0.73; 1.27]0.96 [0.73;1.27]atezolizumab plus nab-paclitaxel vs. talazoparib 0.96 [0.73; 1.27]atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.99 [0.57; 1.72]0.99 [0.57;1.72]atezolizumab plus nab-paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.99 [0.57; 1.72]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus nab-paclitaxel 0.85 [0.31; 2.34]0.85 [0.31;2.34]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus nab-paclitaxel 0.85 [0.31; 2.34]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus paclitaxel 0.62 [0.22; 1.72]0.62 [0.22;1.72]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. atezolizumab plus paclitaxel 0.62 [0.22; 1.72]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. capivasertib plus paclitaxel 1.23 [0.41; 3.69]1.23 [0.41;3.69]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. capivasertib plus paclitaxel 1.23 [0.41; 3.69]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. ipatasertib plus paclitaxel 0.86 [0.28; 2.62]0.86 [0.28;2.62]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. ipatasertib plus paclitaxel 0.86 [0.28; 2.62]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. olaparib 0.77 [0.27; 2.20]0.77 [0.27;2.20]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. olaparib 0.77 [0.27; 2.20]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab alone 0.77 [0.28; 2.11]0.77 [0.28;2.11]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab alone 0.77 [0.28; 2.11]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab plus SoC 0.81 [0.29; 2.23]0.81 [0.29;2.23]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. pembrolizumab plus SoC 0.81 [0.29; 2.23]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo 0.52 [0.17; 1.59]0.52 [0.17;1.59]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. placebo 0.52 [0.17; 1.59]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. sacituzumab govitecan 1.39 [0.50; 3.85]1.39 [0.50;3.85]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. sacituzumab govitecan 1.39 [0.50; 3.85]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. Standard of Care (SoC) 0.69 [0.25; 1.89]0.69 [0.25;1.89]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. Standard of Care (SoC) 0.69 [0.25; 1.89]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. talazoparib 0.81 [0.29; 2.29]0.81 [0.29;2.29]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. talazoparib 0.81 [0.29; 2.29]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. veliparib plus paclitaxel plus carboplatin 0.84 [0.27; 2.62]0.84 [0.27;2.62]atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide vs. veliparib plus paclitaxel plus carboplatin 0.84 [0.27; 2.62]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.37 [1.07; 1.77]1.37 [1.07;1.77]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.37 [1.07; 1.77]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.62 [0.58; 4.52]1.62 [0.58;4.52]atezolizumab plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.62 [0.58; 4.52]atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.99 [1.21; 3.26]1.99 [1.21;3.26]atezolizumab plus paclitaxel vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.99 [1.21; 3.26]atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel 1.40 [0.84; 2.33]1.40 [0.84;2.33]atezolizumab plus paclitaxel vs. ipatasertib plus paclitaxel 1.40 [0.84; 2.33]atezolizumab plus paclitaxel vs. olaparib 1.24 [0.85; 1.80]1.24 [0.85;1.80]atezolizumab plus paclitaxel vs. olaparib 1.24 [0.85; 1.80]atezolizumab plus paclitaxel vs. pembrolizumab alone 1.24 [0.98; 1.57]1.24 [0.98;1.57]atezolizumab plus paclitaxel vs. pembrolizumab alone 1.24 [0.98; 1.57]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.31 [1.04; 1.66]1.31 [1.04;1.66]atezolizumab plus paclitaxel vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.31 [1.04; 1.66]atezolizumab plus paclitaxel vs. placebo 0.84 [0.50; 1.42]0.84 [0.50;1.42]atezolizumab plus paclitaxel vs. placebo 0.84 [0.50; 1.42]atezolizumab plus paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 2.25 [1.75; 2.91]2.25 [1.75;2.91]atezolizumab plus paclitaxel vs. sacituzumab govitecan sacituzumab govitecan better 2.25 [1.75; 2.91]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.12 [0.91; 1.37]1.12 [0.91;1.37]atezolizumab plus paclitaxel vs. Standard of Care (SoC) 1.12 [0.91; 1.37]atezolizumab plus paclitaxel vs. talazoparib 1.32 [0.96; 1.80]1.32 [0.96;1.80]atezolizumab plus paclitaxel vs. talazoparib 1.32 [0.96; 1.80]atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.36 [0.77; 2.40]1.36 [0.77;2.40]atezolizumab plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 1.36 [0.77; 2.40]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.69 [0.43; 1.11]0.69 [0.43;1.11]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.69 [0.43; 1.11]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.82 [0.27; 2.45]0.82 [0.27;2.45]capivasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.82 [0.27; 2.45]capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel capivasertib plus paclitaxel better 0.50 [0.31; 0.83]0.50 [0.31;0.83]capivasertib plus paclitaxel vs. atezolizumab plus paclitaxel capivasertib plus paclitaxel better 0.50 [0.31; 0.83]capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel 0.70 [0.37; 1.35]0.70 [0.37;1.35]capivasertib plus paclitaxel vs. ipatasertib plus paclitaxel 0.70 [0.37; 1.35]capivasertib plus paclitaxel vs. olaparib 0.62 [0.36; 1.08]0.62 [0.36;1.08]capivasertib plus paclitaxel vs. olaparib 0.62 [0.36; 1.08]capivasertib plus paclitaxel vs. pembrolizumab alone capivasertib plus paclitaxel better 0.62 [0.39; 0.99]0.62 [0.39;0.99]capivasertib plus paclitaxel vs. pembrolizumab alone capivasertib plus paclitaxel better 0.62 [0.39; 0.99]capivasertib plus paclitaxel vs. pembrolizumab plus SoC 0.66 [0.42; 1.05]0.66 [0.42;1.05]capivasertib plus paclitaxel vs. pembrolizumab plus SoC 0.66 [0.42; 1.05]capivasertib plus paclitaxel vs. placebo capivasertib plus paclitaxel better 0.42 [0.22; 0.82]0.42 [0.22;0.82]capivasertib plus paclitaxel vs. placebo capivasertib plus paclitaxel better 0.42 [0.22; 0.82]capivasertib plus paclitaxel vs. sacituzumab govitecan 1.13 [0.71; 1.82]1.13 [0.71;1.82]capivasertib plus paclitaxel vs. sacituzumab govitecan 1.13 [0.71; 1.82]capivasertib plus paclitaxel vs. Standard of Care (SoC) capivasertib plus paclitaxel better 0.56 [0.36; 0.88]0.56 [0.36;0.88]capivasertib plus paclitaxel vs. Standard of Care (SoC) capivasertib plus paclitaxel better 0.56 [0.36; 0.88]capivasertib plus paclitaxel vs. talazoparib 0.66 [0.40; 1.10]0.66 [0.40;1.10]capivasertib plus paclitaxel vs. talazoparib 0.66 [0.40; 1.10]capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.69 [0.34; 1.37]0.69 [0.34;1.37]capivasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.69 [0.34; 1.37]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.98 [0.60; 1.61]0.98 [0.60;1.61]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitaxel 0.98 [0.60; 1.61]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.16 [0.38; 3.52]1.16 [0.38;3.52]ipatasertib plus paclitaxel vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.16 [0.38; 3.52]ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel 0.72 [0.43; 1.20]0.72 [0.43;1.20]ipatasertib plus paclitaxel vs. atezolizumab plus paclitaxel 0.72 [0.43; 1.20]ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel 1.42 [0.74; 2.73]1.42 [0.74;2.73]ipatasertib plus paclitaxel vs. capivasertib plus paclitaxel 1.42 [0.74; 2.73]ipatasertib plus paclitaxel vs. olaparib 0.89 [0.51; 1.56]0.89 [0.51;1.56]ipatasertib plus paclitaxel vs. olaparib 0.89 [0.51; 1.56]ipatasertib plus paclitaxel vs. pembrolizumab alone 0.89 [0.55; 1.44]0.89 [0.55;1.44]ipatasertib plus paclitaxel vs. pembrolizumab alone 0.89 [0.55; 1.44]ipatasertib plus paclitaxel vs. pembrolizumab plus SoC 0.94 [0.58; 1.52]0.94 [0.58;1.52]ipatasertib plus paclitaxel vs. pembrolizumab plus SoC 0.94 [0.58; 1.52]ipatasertib plus paclitaxel vs. placebo 0.60 [0.31; 1.18]0.60 [0.31;1.18]ipatasertib plus paclitaxel vs. placebo 0.60 [0.31; 1.18]ipatasertib plus paclitaxel vs. sacituzumab govitecan 1.61 [0.99; 2.64]1.61 [0.99;2.64]ipatasertib plus paclitaxel vs. sacituzumab govitecan 1.61 [0.99; 2.64]ipatasertib plus paclitaxel vs. Standard of Care (SoC) 0.80 [0.50; 1.28]0.80 [0.50;1.28]ipatasertib plus paclitaxel vs. Standard of Care (SoC) 0.80 [0.50; 1.28]ipatasertib plus paclitaxel vs. talazoparib 0.94 [0.56; 1.60]0.94 [0.56;1.60]ipatasertib plus paclitaxel vs. talazoparib 0.94 [0.56; 1.60]ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.98 [0.48; 1.98]0.98 [0.48;1.98]ipatasertib plus paclitaxel vs. veliparib plus paclitaxel plus carboplatin 0.98 [0.48; 1.98]olaparib vs. atezolizumab plus nab-paclitaxel 1.10 [0.78; 1.56]1.10 [0.78;1.56]olaparib vs. atezolizumab plus nab-paclitaxel 1.10 [0.78; 1.56]olaparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.30 [0.46; 3.74]1.30 [0.46;3.74]olaparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.30 [0.46; 3.74]olaparib vs. atezolizumab plus paclitaxel 0.81 [0.55; 1.17]0.81 [0.55;1.17]olaparib vs. atezolizumab plus paclitaxel 0.81 [0.55; 1.17]olaparib vs. capivasertib plus paclitaxel 1.60 [0.93; 2.77]1.60 [0.93;2.77]olaparib vs. capivasertib plus paclitaxel 1.60 [0.93; 2.77]olaparib vs. ipatasertib plus paclitaxel 1.12 [0.64; 1.98]1.12 [0.64;1.98]olaparib vs. ipatasertib plus paclitaxel 1.12 [0.64; 1.98]olaparib vs. pembrolizumab alone 1.00 [0.71; 1.39]1.00 [0.71;1.39]olaparib vs. pembrolizumab alone 1.00 [0.71; 1.39]olaparib vs. pembrolizumab plus SoC 1.06 [0.76; 1.47]1.06 [0.76;1.47]olaparib vs. pembrolizumab plus SoC 1.06 [0.76; 1.47]olaparib vs. placebo olaparib better 0.68 [0.47; 0.98]0.68 [0.47;0.98]olaparib vs. placebo olaparib better 0.68 [0.47; 0.98]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]1.82 [1.28;2.57]olaparib vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.28; 2.57]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]0.90 [0.66;1.23]olaparib vs. Standard of Care (SoC) 0.90 [0.66; 1.23]olaparib vs. talazoparib 1.06 [0.72; 1.57]1.06 [0.72;1.57]olaparib vs. talazoparib 1.06 [0.72; 1.57]olaparib vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.59; 2.03]1.10 [0.59;2.03]olaparib vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.59; 2.03]pembrolizumab alone vs. atezolizumab plus nab-paclitaxel 1.11 [0.91; 1.34]1.11 [0.91;1.34]pembrolizumab alone vs. atezolizumab plus nab-paclitaxel 1.11 [0.91; 1.34]pembrolizumab alone vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.31 [0.47; 3.60]1.31 [0.47;3.60]pembrolizumab alone vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.31 [0.47; 3.60]pembrolizumab alone vs. atezolizumab plus paclitaxel 0.81 [0.64; 1.03]0.81 [0.64;1.03]pembrolizumab alone vs. atezolizumab plus paclitaxel 0.81 [0.64; 1.03]pembrolizumab alone vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.60 [1.01; 2.56]1.60 [1.01;2.56]pembrolizumab alone vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.60 [1.01; 2.56]pembrolizumab alone vs. ipatasertib plus paclitaxel 1.13 [0.69; 1.83]1.13 [0.69;1.83]pembrolizumab alone vs. ipatasertib plus paclitaxel 1.13 [0.69; 1.83]pembrolizumab alone vs. olaparib 1.00 [0.72; 1.40]1.00 [0.72;1.40]pembrolizumab alone vs. olaparib 1.00 [0.72; 1.40]pembrolizumab alone vs. pembrolizumab plus SoC 1.06 [0.90; 1.25]1.06 [0.90;1.25]pembrolizumab alone vs. pembrolizumab plus SoC 1.06 [0.90; 1.25]pembrolizumab alone vs. placebo 0.68 [0.42; 1.12]0.68 [0.42;1.12]pembrolizumab alone vs. placebo 0.68 [0.42; 1.12]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.50; 2.21]1.82 [1.50;2.21]pembrolizumab alone vs. sacituzumab govitecan sacituzumab govitecan better 1.82 [1.50; 2.21]pembrolizumab alone vs. Standard of Care (SoC) 0.90 [0.80; 1.02]0.90 [0.80;1.02]pembrolizumab alone vs. Standard of Care (SoC) 0.90 [0.80; 1.02]pembrolizumab alone vs. talazoparib 1.06 [0.82; 1.39]1.06 [0.82;1.39]pembrolizumab alone vs. talazoparib 1.06 [0.82; 1.39]pembrolizumab alone vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.64; 1.89]1.10 [0.64;1.89]pembrolizumab alone vs. veliparib plus paclitaxel plus carboplatin 1.10 [0.64; 1.89]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.04 [0.87; 1.26]1.04 [0.87;1.26]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitaxel 1.04 [0.87; 1.26]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.45; 3.39]1.23 [0.45;3.39]pembrolizumab plus SoC vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.45; 3.39]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel pembrolizumab plus SoC better 0.76 [0.60; 0.96]0.76 [0.60;0.96]pembrolizumab plus SoC vs. atezolizumab plus paclitaxel pembrolizumab plus SoC better 0.76 [0.60; 0.96]pembrolizumab plus SoC vs. capivasertib plus paclitaxel 1.51 [0.95; 2.41]1.51 [0.95;2.41]pembrolizumab plus SoC vs. capivasertib plus paclitaxel 1.51 [0.95; 2.41]pembrolizumab plus SoC vs. ipatasertib plus paclitaxel 1.06 [0.66; 1.72]1.06 [0.66;1.72]pembrolizumab plus SoC vs. ipatasertib plus paclitaxel 1.06 [0.66; 1.72]pembrolizumab plus SoC vs. olaparib 0.95 [0.68; 1.32]0.95 [0.68;1.32]pembrolizumab plus SoC vs. olaparib 0.95 [0.68; 1.32]pembrolizumab plus SoC vs. pembrolizumab alone 0.94 [0.80; 1.11]0.94 [0.80;1.11]pembrolizumab plus SoC vs. pembrolizumab alone 0.94 [0.80; 1.11]pembrolizumab plus SoC vs. placebo 0.64 [0.39; 1.05]0.64 [0.39;1.05]pembrolizumab plus SoC vs. placebo 0.64 [0.39; 1.05]pembrolizumab plus SoC vs. sacituzumab govitecan sacituzumab govitecan better 1.72 [1.42; 2.07]1.72 [1.42;2.07]pembrolizumab plus SoC vs. sacituzumab govitecan sacituzumab govitecan better 1.72 [1.42; 2.07]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.85 [0.76; 0.95]0.85 [0.76;0.95]pembrolizumab plus SoC vs. Standard of Care (SoC) pembrolizumab plus SoC better 0.85 [0.76; 0.95]pembrolizumab plus SoC vs. talazoparib 1.00 [0.77; 1.30]1.00 [0.77;1.30]pembrolizumab plus SoC vs. talazoparib 1.00 [0.77; 1.30]pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin 1.04 [0.60; 1.78]1.04 [0.60;1.78]pembrolizumab plus SoC vs. veliparib plus paclitaxel plus carboplatin 1.04 [0.60; 1.78]placebo vs. atezolizumab plus nab-paclitaxel 1.62 [0.99; 2.68]1.62 [0.99;2.68]placebo vs. atezolizumab plus nab-paclitaxel 1.62 [0.99; 2.68]placebo vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.92 [0.63; 5.84]1.92 [0.63;5.84]placebo vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.92 [0.63; 5.84]placebo vs. atezolizumab plus paclitaxel 1.18 [0.70; 1.99]1.18 [0.70;1.99]placebo vs. atezolizumab plus paclitaxel 1.18 [0.70; 1.99]placebo vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 2.35 [1.22; 4.54]2.35 [1.22;4.54]placebo vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 2.35 [1.22; 4.54]placebo vs. ipatasertib plus paclitaxel 1.65 [0.85; 3.23]1.65 [0.85;3.23]placebo vs. ipatasertib plus paclitaxel 1.65 [0.85; 3.23]placebo vs. olaparib olaparib better 1.47 [1.02; 2.11]1.47 [1.02;2.11]placebo vs. olaparib olaparib better 1.47 [1.02; 2.11]placebo vs. pembrolizumab alone 1.47 [0.90; 2.40]1.47 [0.90;2.40]placebo vs. pembrolizumab alone 1.47 [0.90; 2.40]placebo vs. pembrolizumab plus SoC 1.56 [0.95; 2.54]1.56 [0.95;2.54]placebo vs. pembrolizumab plus SoC 1.56 [0.95; 2.54]placebo vs. sacituzumab govitecan sacituzumab govitecan better 2.67 [1.62; 4.41]2.67 [1.62;4.41]placebo vs. sacituzumab govitecan sacituzumab govitecan better 2.67 [1.62; 4.41]placebo vs. Standard of Care (SoC) 1.32 [0.82; 2.13]1.32 [0.82;2.13]placebo vs. Standard of Care (SoC) 1.32 [0.82; 2.13]placebo vs. talazoparib 1.56 [0.92; 2.66]1.56 [0.92;2.66]placebo vs. talazoparib 1.56 [0.92; 2.66]placebo vs. veliparib plus paclitaxel plus carboplatin 1.61 [0.79; 3.29]1.61 [0.79;3.29]placebo vs. veliparib plus paclitaxel plus carboplatin 1.61 [0.79; 3.29]sacituzumab govitecan vs. atezolizumab plus nab-paclitaxel sacituzumab govitecan better 0.61 [0.49; 0.75]0.61 [0.49;0.75]sacituzumab govitecan vs. atezolizumab plus nab-paclitaxel sacituzumab govitecan better 0.61 [0.49; 0.75]sacituzumab govitecan vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.72 [0.26; 1.99]0.72 [0.26;1.99]sacituzumab govitecan vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 0.72 [0.26; 1.99]sacituzumab govitecan vs. atezolizumab plus paclitaxel sacituzumab govitecan better 0.44 [0.34; 0.57]0.44 [0.34;0.57]sacituzumab govitecan vs. atezolizumab plus paclitaxel sacituzumab govitecan better 0.44 [0.34; 0.57]sacituzumab govitecan vs. capivasertib plus paclitaxel 0.88 [0.55; 1.42]0.88 [0.55;1.42]sacituzumab govitecan vs. capivasertib plus paclitaxel 0.88 [0.55; 1.42]sacituzumab govitecan vs. ipatasertib plus paclitaxel 0.62 [0.38; 1.02]0.62 [0.38;1.02]sacituzumab govitecan vs. ipatasertib plus paclitaxel 0.62 [0.38; 1.02]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]0.55 [0.39;0.78]sacituzumab govitecan vs. olaparib sacituzumab govitecan better 0.55 [0.39; 0.78]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.55 [0.45; 0.67]0.55 [0.45;0.67]sacituzumab govitecan vs. pembrolizumab alone sacituzumab govitecan better 0.55 [0.45; 0.67]sacituzumab govitecan vs. pembrolizumab plus SoC sacituzumab govitecan better 0.58 [0.48; 0.70]0.58 [0.48;0.70]sacituzumab govitecan vs. pembrolizumab plus SoC sacituzumab govitecan better 0.58 [0.48; 0.70]sacituzumab govitecan vs. placebo sacituzumab govitecan better 0.37 [0.23; 0.62]0.37 [0.23;0.62]sacituzumab govitecan vs. placebo sacituzumab govitecan better 0.37 [0.23; 0.62]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]0.50 [0.43;0.58]sacituzumab govitecan vs. Standard of Care (SoC) sacituzumab govitecan better 0.50 [0.43; 0.58]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]0.58 [0.44;0.77]sacituzumab govitecan vs. talazoparib sacituzumab govitecan better 0.58 [0.44; 0.77]sacituzumab govitecan vs. veliparib plus paclitaxel plus carboplatin 0.60 [0.35; 1.05]0.60 [0.35;1.05]sacituzumab govitecan vs. veliparib plus paclitaxel plus carboplatin 0.60 [0.35; 1.05]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.23 [1.06; 1.42]1.23 [1.06;1.42]Standard of Care (SoC) vs. atezolizumab plus nab-paclitaxel atezolizumab plus nab-paclitaxel better 1.23 [1.06; 1.42]Standard of Care (SoC) vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.45 [0.53; 3.96]1.45 [0.53;3.96]Standard of Care (SoC) vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.45 [0.53; 3.96]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.73; 1.10]0.90 [0.73;1.10]Standard of Care (SoC) vs. atezolizumab plus paclitaxel 0.90 [0.73; 1.10]Standard of Care (SoC) vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.78 [1.13; 2.79]1.78 [1.13;2.79]Standard of Care (SoC) vs. capivasertib plus paclitaxel capivasertib plus paclitaxel better 1.78 [1.13; 2.79]Standard of Care (SoC) vs. ipatasertib plus paclitaxel 1.25 [0.78; 2.00]1.25 [0.78;2.00]Standard of Care (SoC) vs. ipatasertib plus paclitaxel 1.25 [0.78; 2.00]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]1.11 [0.81;1.52]Standard of Care (SoC) vs. olaparib 1.11 [0.81; 1.52]Standard of Care (SoC) vs. pembrolizumab alone 1.11 [0.98; 1.25]1.11 [0.98;1.25]Standard of Care (SoC) vs. pembrolizumab alone 1.11 [0.98; 1.25]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.18 [1.05; 1.31]1.18 [1.05;1.31]Standard of Care (SoC) vs. pembrolizumab plus SoC pembrolizumab plus SoC better 1.18 [1.05; 1.31]Standard of Care (SoC) vs. placebo 0.76 [0.47; 1.22]0.76 [0.47;1.22]Standard of Care (SoC) vs. placebo 0.76 [0.47; 1.22]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]2.02 [1.74;2.35]Standard of Care (SoC) vs. sacituzumab govitecan sacituzumab govitecan better 2.02 [1.74; 2.35]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]1.18 [0.93;1.49]Standard of Care (SoC) vs. talazoparib 1.18 [0.93; 1.49]Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin 1.22 [0.72; 2.07]1.22 [0.72;2.07]Standard of Care (SoC) vs. veliparib plus paclitaxel plus carboplatin 1.22 [0.72; 2.07]talazoparib vs. atezolizumab plus nab-paclitaxel 1.04 [0.79; 1.37]1.04 [0.79;1.37]talazoparib vs. atezolizumab plus nab-paclitaxel 1.04 [0.79; 1.37]talazoparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.44; 3.45]1.23 [0.44;3.45]talazoparib vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.23 [0.44; 3.45]talazoparib vs. atezolizumab plus paclitaxel 0.76 [0.56; 1.04]0.76 [0.56;1.04]talazoparib vs. atezolizumab plus paclitaxel 0.76 [0.56; 1.04]talazoparib vs. capivasertib plus paclitaxel 1.51 [0.91; 2.51]1.51 [0.91;2.51]talazoparib vs. capivasertib plus paclitaxel 1.51 [0.91; 2.51]talazoparib vs. ipatasertib plus paclitaxel 1.06 [0.63; 1.79]1.06 [0.63;1.79]talazoparib vs. ipatasertib plus paclitaxel 1.06 [0.63; 1.79]talazoparib vs. olaparib 0.94 [0.64; 1.39]0.94 [0.64;1.39]talazoparib vs. olaparib 0.94 [0.64; 1.39]talazoparib vs. pembrolizumab alone 0.94 [0.72; 1.23]0.94 [0.72;1.23]talazoparib vs. pembrolizumab alone 0.94 [0.72; 1.23]talazoparib vs. pembrolizumab plus SoC 1.00 [0.77; 1.29]1.00 [0.77;1.29]talazoparib vs. pembrolizumab plus SoC 1.00 [0.77; 1.29]talazoparib vs. placebo 0.64 [0.38; 1.09]0.64 [0.38;1.09]talazoparib vs. placebo 0.64 [0.38; 1.09]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]1.71 [1.29;2.26]talazoparib vs. sacituzumab govitecan sacituzumab govitecan better 1.71 [1.29; 2.26]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]0.85 [0.67;1.07]talazoparib vs. Standard of Care (SoC) 0.85 [0.67; 1.07]talazoparib vs. veliparib plus paclitaxel plus carboplatin 1.03 [0.58; 1.84]1.03 [0.58;1.84]talazoparib vs. veliparib plus paclitaxel plus carboplatin 1.03 [0.58; 1.84]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel 1.01 [0.58; 1.74]1.01 [0.58;1.74]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitaxel 1.01 [0.58; 1.74]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.19 [0.38; 3.70]1.19 [0.38;3.70]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide 1.19 [0.38; 3.70]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel 0.73 [0.42; 1.29]0.73 [0.42;1.29]veliparib plus paclitaxel plus carboplatin vs. atezolizumab plus paclitaxel 0.73 [0.42; 1.29]veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel 1.46 [0.73; 2.92]1.46 [0.73;2.92]veliparib plus paclitaxel plus carboplatin vs. capivasertib plus paclitaxel 1.46 [0.73; 2.92]veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel 1.02 [0.51; 2.08]1.02 [0.51;2.08]veliparib plus paclitaxel plus carboplatin vs. ipatasertib plus paclitaxel 1.02 [0.51; 2.08]veliparib plus paclitaxel plus carboplatin vs. olaparib 0.91 [0.49; 1.68]0.91 [0.49;1.68]veliparib plus paclitaxel plus carboplatin vs. olaparib 0.91 [0.49; 1.68]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab alone 0.91 [0.53; 1.56]0.91 [0.53;1.56]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab alone 0.91 [0.53; 1.56]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC 0.96 [0.56; 1.65]0.96 [0.56;1.65]veliparib plus paclitaxel plus carboplatin vs. pembrolizumab plus SoC 0.96 [0.56; 1.65]veliparib plus paclitaxel plus carboplatin vs. placebo 0.62 [0.30; 1.26]0.62 [0.30;1.26]veliparib plus paclitaxel plus carboplatin vs. placebo 0.62 [0.30; 1.26]veliparib plus paclitaxel plus carboplatin vs. sacituzumab govitecan 1.65 [0.96; 2.86]1.65 [0.96;2.86]veliparib plus paclitaxel plus carboplatin vs. sacituzumab govitecan 1.65 [0.96; 2.86]veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC) 0.82 [0.48; 1.39]0.82 [0.48;1.39]veliparib plus paclitaxel plus carboplatin vs. Standard of Care (SoC) 0.82 [0.48; 1.39]veliparib plus paclitaxel plus carboplatin vs. talazoparib 0.97 [0.54; 1.72]0.97 [0.54;1.72]veliparib plus paclitaxel plus carboplatin vs. talazoparib 0.97 [0.54; 1.72]placeboStandard of Care (SoC)placebo plus SoCcarboplatin plus nab-paclitaxeldurvalumab alonepembrolizumab aloneatezolizumab plus nab-paclitaxelatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamideatezolizumab plus paclitaxelatezolizumab plus carboplatin plus nab-paclitaxeltalazoparibolaparibpembrolizumab plus SoCsacituzumab govitecancapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatindirect evidencenetwork meta-analysis
T vs. C placeboStandard of Care (SoC)placebo plus SoCcarboplatin plus nab-paclitaxeldurvalumab alonepembrolizumab aloneatezolizumab plus nab-paclitaxelatezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamideatezolizumab plus paclitaxelatezolizumab plus carboplatin plus nab-paclitaxeltalazoparibolaparibpembrolizumab plus SoCsacituzumab govitecancapivasertib plus paclitaxelipatasertib plus paclitaxelveliparib plus paclitaxel plus carboplatin
placebo---1.32
0.82; 2.13		NANANA1.47
0.90; 2.40		1.62
0.99; 2.68		1.92
0.63; 5.84		1.18
0.70; 1.99		NA1.56
0.92; 2.66		1.47
1.02; 2.11		1.56
0.95; 2.54		2.67
1.62; 4.41		2.35
1.22; 4.54		1.65
0.85; 3.23		1.61
0.79; 3.29
Standard of Care (SoC)0.76
0.47; 1.22		---NANANA1.11
0.98; 1.25		1.23
1.06; 1.42		1.45
0.53; 3.96		0.90
0.73; 1.10		NA1.18
0.93; 1.49		1.11
0.81; 1.52		1.18
1.05; 1.31		2.02
1.74; 2.35		1.78
1.13; 2.79		1.25
0.78; 2.00		1.22
0.72; 2.07
placebo plus SoCNANA---NANANANANANANANANANANANANANA
carboplatin plus nab-paclitaxelNANANA---NANANANANANANANANANANANANA
durvalumab aloneNANANANA---NANANANANANANANANANANANA
pembrolizumab alone0.68
0.42; 1.12		0.90
0.80; 1.02		NANANA---1.11
0.91; 1.34		1.31
0.47; 3.60		0.81
0.64; 1.03		NA1.06
0.82; 1.39		1.00
0.72; 1.40		1.06
0.90; 1.25		1.82
1.50; 2.21		1.60
1.01; 2.56		1.13
0.69; 1.83		1.10
0.64; 1.89
atezolizumab plus nab-paclitaxel0.62
0.37; 1.01		0.81
0.70; 0.94		NANANA0.90
0.75; 1.09		---1.18
0.43; 3.26		0.73
0.57; 0.94		NA0.96
0.73; 1.27		0.91
0.64; 1.28		0.96
0.80; 1.15		1.64
1.33; 2.03		1.45
0.90; 2.33		1.02
0.62; 1.67		0.99
0.57; 1.72
atezolizumab plus nab-paclitxel followed by doxorubicin plus cyclophosphamide0.52
0.17; 1.59		0.69
0.25; 1.89		NANANA0.77
0.28; 2.11		0.85
0.31; 2.34		---0.62
0.22; 1.72		NA0.81
0.29; 2.29		0.77
0.27; 2.20		0.81
0.29; 2.23		1.39
0.50; 3.85		1.23
0.41; 3.69		0.86
0.28; 2.62		0.84
0.27; 2.62
atezolizumab plus paclitaxel0.84
0.50; 1.42		1.12
0.91; 1.37		NANANA1.24
0.98; 1.57		1.37
1.07; 1.77		1.62
0.58; 4.52		---NA1.32
0.96; 1.80		1.24
0.85; 1.80		1.31
1.04; 1.66		2.25
1.75; 2.91		1.99
1.21; 3.26		1.40
0.84; 2.33		1.36
0.77; 2.40
atezolizumab plus carboplatin plus nab-paclitaxelNANANANANANANANANA---NANANANANANANA
talazoparib0.64
0.38; 1.09		0.85
0.67; 1.07		NANANA0.94
0.72; 1.23		1.04
0.79; 1.37		1.23
0.44; 3.45		0.76
0.56; 1.04		NA---0.94
0.64; 1.39		1.00
0.77; 1.29		1.71
1.29; 2.26		1.51
0.91; 2.51		1.06
0.63; 1.79		1.03
0.58; 1.84
olaparib0.68
0.47; 0.98		0.90
0.66; 1.23		NANANA1.00
0.71; 1.39		1.10
0.78; 1.56		1.30
0.46; 3.74		0.81
0.55; 1.17		NA1.06
0.72; 1.57		---1.06
0.76; 1.47		1.82
1.28; 2.57		1.60
0.93; 2.77		1.12
0.64; 1.98		1.10
0.59; 2.03
pembrolizumab plus SoC0.64
0.39; 1.05		0.85
0.76; 0.95		NANANA0.94
0.80; 1.11		1.04
0.87; 1.26		1.23
0.45; 3.39		0.76
0.60; 0.96		NA1.00
0.77; 1.30		0.95
0.68; 1.32		---1.72
1.42; 2.07		1.51
0.95; 2.41		1.06
0.66; 1.72		1.04
0.60; 1.78
sacituzumab govitecan0.37
0.23; 0.62		0.50
0.43; 0.58		NANANA0.55
0.45; 0.67		0.61
0.49; 0.75		0.72
0.26; 1.99		0.44
0.34; 0.57		NA0.58
0.44; 0.77		0.55
0.39; 0.78		0.58
0.48; 0.70		---0.88
0.55; 1.42		0.62
0.38; 1.02		0.60
0.35; 1.05
capivasertib plus paclitaxel0.42
0.22; 0.82		0.56
0.36; 0.88		NANANA0.62
0.39; 0.99		0.69
0.43; 1.11		0.82
0.27; 2.45		0.50
0.31; 0.83		NA0.66
0.40; 1.10		0.62
0.36; 1.08		0.66
0.42; 1.05		1.13
0.71; 1.82		---0.70
0.37; 1.35		0.69
0.34; 1.37
ipatasertib plus paclitaxel0.60
0.31; 1.18		0.80
0.50; 1.28		NANANA0.89
0.55; 1.44		0.98
0.60; 1.61		1.16
0.38; 3.52		0.72
0.43; 1.20		NA0.94
0.56; 1.60		0.89
0.51; 1.56		0.94
0.58; 1.52		1.61
0.99; 2.64		1.42
0.74; 2.73		---0.98
0.48; 1.98
veliparib plus paclitaxel plus carboplatin0.62
0.30; 1.26		0.82
0.48; 1.39		NANANA0.91
0.53; 1.56		1.01
0.58; 1.74		1.19
0.38; 3.70		0.73
0.42; 1.29		NA0.97
0.54; 1.72		0.91
0.49; 1.68		0.96
0.56; 1.65		1.65
0.96; 2.86		1.46
0.73; 2.92		1.02
0.51; 2.08		---

pathologies: 324,142,305,306,98,96,269,60,143,270,140,240 - treatments: 1252 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons